Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Oct 1, 2015
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

NCI CTEP-Approved Trials For the Month of September

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9834: A Phase I Study of Methoxyamine Combined with Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer. Case Western Reserve University; Biswas, Tithi. (216) 286-6740

 

9874: A Phase I Trial of AT13387 in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin. University Health Network Princess Margaret Cancer Center LAO; Hope, Andrew J. (416) 946-2124

 

ADVL1416: A Phase 1 Study of Ramucirumab, a Human, Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors. COG Phase 1 Consortium; Pradhan, Kamnesh. (317) 944-8784

 

Phase I/II

9837: Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Cisplatin and Pemetrexed. City of Hope Comprehensive Cancer Center LAO; Koczywas, Marianna. (626) 256-4673

 

Phase II

A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations. Alliance for Clinical Trials in Oncology; Brastianos, Priscilla Kaliopi. (617) 643-1938

 

A221208: Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases. Alliance for Clinical Trials in Oncology; Chung, Caroline. (416) 946-4501 X 6513

 

EA2142: Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas. ECOG-ACRIN Cancer Research Group; Eads, Jennifer Rachel. (216) 844-6003

 

Phase II/III

EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma. ECOG-ACRIN Cancer Research Group; Hodi, Frank Stephen. (617) 632-5053

 

Phase III

AAML1531: Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome. Children’s Oncology Group; Berman, Jason Noah. (902) 470-8048

 

WF-01115: Community Hospital Identification of High CV Risk Patients during Cancer Treatment (CHI). Wake Forest NCORP Research Base; Hundley, William Gregory. (336) 716-0607

 

Other Phases

9905: Prognostic Implications of Tumor Infiltrating Lymphocytes (TILs) in Primary HER2-Positive Breast Cancer Treated with Trastuzumab or Combination Trastuzumab and Lapatinib. Peter MacCallum Cancer Centre; Loi, Sherene. 61-3-9656-1804

 

AALL15B5-Q: Development of the Next Generation FLT3 Inhibitors for Infant ALL. Children’s Oncology Group; Small, Donald. (410) 614-0994

 

AHOD15B1-Q: Evaluation of B2M and XPO1 Genomic Alterations in Pediatric Classic Hodgkin Lymphoma (cHL). Children’s Oncology Group; Roth, Lisa Giulino. (212) 746-3400

 

EA915LT1: The Aging Epigenome and Its Contribution to MDS Development. ECOG-ACRIN Cancer Research Group; Figueroa, Maria E. (734) 763-1865



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter